Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma

BACKGROUND: Nivolumab, an anti-programmed cell death-1 monoclonal antibody, has improved the survival of patients with malignant melanoma. Despite its efficacy, nivolumab inconsistently induces thyroid dysfunction as an immune-related adverse event (irAE). This study aimed to evaluate nivolumab-indu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yano, Seiichi, Ashida, Kenji, Nagata, Hiromi, Ohe, Kenji, Wada, Naoko, Takeichi, Yukina, Hanada, Yuki, Ibayashi, Yuta, Wang, Lixiang, Sakamoto, Shohei, Sakamoto, Ryuichi, Uchi, Hiroshi, Shiratsuchi, Motoaki, Furue, Masutaka, Nomura, Masatoshi, Ogawa, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994101/
https://www.ncbi.nlm.nih.gov/pubmed/29884162
http://dx.doi.org/10.1186/s12902-018-0267-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994101/
https://www.ncbi.nlm.nih.gov/pubmed/29884162
http://dx.doi.org/10.1186/s12902-018-0267-x

Ejemplares similares